Welcure Drugs & Pharmaceuticals Ltd (WELCURE) is currently trading at 0.21 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Welcure Drugs And Pharmaceuticals (WDPL) is engaged in the manufacture of bulk drugs and pharmaceutical formulations, including antibiotics and vitamins, offering over a hundred varieties of products. The company has a strategic collaboration agreement with a Russian firm to be the sole selling agent for Stevioside, a sugar substitute, enhancing its portfolio and market reach. Welcure has diversified its product line by adding sections for paediatric and veterinary drugs, as well as expanding into ointments and liquid syrups. It boasts a strong infrastructure with a new liquid oral plant and ISO 9002 certification, ensuring high quality and standards for its products.

Over the past 52 weeks, Welcure Drugs & Pharmaceuticals Ltd has traded between a low of ₹0.19 and a high of ₹0.81. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of approximately 27.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Welcure Drugs & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 27.19 Cr, Welcure Drugs & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Welcure Drugs & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Welcure Drugs & Pharmaceuticals Ltd is -1.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay, is the most significant announcement. It aims to boost domestic pharma manufacturing and streamline regulatory approvals through a strengthened CDSCO, benefiting the entire sector.